Latest News

  • Chairman’s Letter for National Breast Cancer Awa...

    As we start Breast Cancer Awareness Month for 2016 we remember all our friends and loved ones who have been affected by cancer.  Over the past year, we have seen amazing progress in the field of...

    Read more

  • TapImmune Announces Reverse Stock Split in Prepara...

    JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune Issues Update: Multiple Phase 2 Trials, ...

    JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune Appoints Michael J. Loiacono as Chief Fi...

    Accomplished Financial Director & CFO of Public Companies August 25, 2016, Jacksonville, FL,, TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the...

    Read more

  • TAPIMMUNE RECOGNIZES MARY WASHBURN BINKLEY, HER FA...

    Mary lives her life through her Christian faith, dedication to her family and through service to others. She is an alumni of the University of Tennessee, Knoxville, and her family are avid Tennessee...

    Read more

  • TapImmune Enters into Definitive Agreements to rai...

    Company has Applied for Listing on Nasdaq Capital Market JACKSONVILLE, Florida, August 11, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of...

    Read more

  • Tampa executive takes key post at a Jacksonville b...

    A bioscience veteran in Tampa has been named president and chief operating officer of TapImmune Inc., a Jacksonville company developing a vaccine to treat cancer. John Bonfiglio — formerly the...

    Read more

  • TapImmune Appoints Dr. John N. Bonfiglio as Presid...

    JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • Q&A with TapImmune CEO Dr. Glynn Wilson, on a...

    A vaccine that can prevent the recurrence and metastasis of cancer would save countless lives. In the past century, vaccines have virtually eradicated life threatening diseases including polio and...

    Read more

  • TapImmune Doses First Patient in its Phase 2 Tripl...

    Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016 JACKSONVILLE, FL, June 21, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the...

    Read more

  • TAPIMMUNE ANNOUNCES FINALIZATION OF LICENSE AGREEM...

     Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials Jacksonville FL, June 7, 2016 – TapImmune, Inc. (OTCQB:...

    Read more

  • TapImmune to Present at the LD Micro Invitational ...

    JACKSONVILLE, FL, June 6, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune to Present at SeeThruEquity and Marcum C...

    TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

    Read more

  • TapImmune to Present at the 3rd Annual Growth Capi...

    JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune Announces Phase 2 Ovarian Cancer Trial S...

    JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in...

    Read more

  • TapImmune Completes GMP Manufacturing and Release ...

    Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage...

    Read more

  • Join TapImmune at Jacksonville’s Immunothera...

    UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership...

    Read more

  • Experts say research shows promise for a breast ca...

    03/31/16 Medicine By Kathleen McGrory, Times staff writer There are vaccines to help the body fight off measles, mumps and the flu. But breast cancer? That’s exactly the technology a...

    Read more

  • Update with TapImmune, Inc. – Discusses Targ...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

Jacksonville-based biotech company applies to uplist on Nasdaq

Jacksonville-Business-Journal

 

 

TapImmune Inc. (OTC: TPIV), the immuno-oncology company that came to Jacksonville a year ago, is moving up in the biotech world, applying for a Nasdaq listing.

The company, which develops peptide and gene-based therapies and vaccines for cancers, is planning to uplist from its over-the-counter listing to the more prestigious Nasdaq Capital Markets.

To do so, it had to meet certain requirements, said CEO Glynn Wilson, such as enough financing for more than a year and positive shareholder equity.

To be listed on the Nasdaq Capital Market, listing requirements include an operating history of 2 years, $5 million in shareholders equity, 1 million publicly held shares and a bid price of $4, according to the Nasdaq initial listing guide. Wilson says the company now has $29 million in shareholder equity and recently raised $9 million in capital.

To be approved for a Nasdaq listing — something the company is still waiting on — would be a big step for TapImmune, putting them more in the biotech spotlight.

“We will get a lot more attention from fundamental investors,” said Wilson. “On the retail side, everyone can buy our stock, so we expect increased volume. And certainly, people who are involved in Nasdaq biotech will look at us much more favorably.”

It comes during a time when TapImmune has four studies in the works, two of which have already started. Of those two, one involves a partnership with Memorial Sloan Kettering in New York and Astra Zeneca for combination therapy.

The other, at the Mayo Clinic, is fully funded by the Department of Defense and is for triple-negative breast cancer, a very aggressive form of cancer.

That study, which takes peptides and injects them into patients that have not had any other form of treatment work, will be a double-blind, 280-patient survey. Wilson said the study will take about 18 months to find all of the patients, and then another three years to complete all the testing. It’s a $13.3 million study.

As the company is on the verge of several new projects that could make breakthroughs in gene-related treatment and immunotherapy, Wilson said the company is already thinking ahead to new, eventual applications for treatment. TapImmune already has tests out for a few types of cancers, including breast cancer, ovarian cancer, lung cancer and colo-rectal cancer. But with peptide treatment, the company just has to train the T-cells to target different cancer cells.

“I think we’re very well positioned in the field on the T-cell vaccine side,” Wilson said. Although TapImmune was based in Seattle, a year ago, Wilson said he chose to move the company to Jacksonville to be closer to the Mayo Clinic and some of the company’s advisers, based in Florida. “We love being in Jacksonville,” he said. “We had a concentration of people ready in Florida. I think the decision to bring the company to Jacksonville will turn out to be a great decision.”

Jensen Werley, Reporter

Jacksonville Business Journal

Article is was originally posted on the Jacksonville Business Journal Web Site.

 

The Wall Street Analyzer – TapImmune Inc OTCQB: TPIV CEO Glynn Wilson, Ph.D. Interview Series

The-Wall-Street-Analyzer

 

 

Listen to TapImmune’s CEO, Glynn Wilson, Ph.D. on That Business Show hosted by: Jamie Meloni

That-Business-Show-Hosted-By-Jamie-Meloni-Featuring-Glynn-WIlson-PhD

Glynn-Wilson-TapImmune-Cancer-Vaccine-WJC-NEWS

Nikolai-Vitti-Glynn-Wilson-TapImmune-Cancer-Vaccine-WJC-NEWS

 

SNNLive Update with TapImmune, Inc. (OTCQB: TPIV) – May 2016

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

JACKSONVILLE, Florida, December 7, 2015 /PRNewswire/

TapImmune (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015 San Antonio Breast Cancer Symposium, which will be held in San Antonio, Texas on December 8 – 12, 2015.

Data will be presented at the poster session, “Treatment: Immunotherapy” on Thursday, December 10, from 7:30 am to 9:00 am. The poster titled, “Robust generation of T-cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine,” was co-authored by Dr. Wilson, Dr. Knutson, Dr Degnim and other researchers from the Mayo Clinic in Rochester, MN.

The poster presentation will include previously unpublished data from a concluded Phase 1 trial conducted at the Mayo Clinic on a T-cell stimulating vaccine (TPIV 100) for the indication of HER2/neu breast cancer.  TapImmune has the Exclusive Option to license this technology from the Mayo Clinic.  The percent of patients that responded with augmented T cell immunity to the four peptide antigens contained in the vaccine was high for each peptide ranging from 68-88%, which led to the 90% of the patients augmenting T cells that recognized naturally processed HER2 antigen.  ”This presentation will present evidence of a robust and significant immune response using antigens designed to target HER2/neu epitopes known to be important targets in a variety of cancers. These are compelling data that has made us excited about initiating development efforts towards a Phase 2 program with this product” stated Dr. Wilson

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website athttp://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements.

Contacts:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

 

Life Sciences Intellectual Property Review

TapImmune featured in Life Sciences Intellectual Property Review

LSIPR logo
Page 1 of 3123